Document is current

Article History

Received: 9 July 2024

Accepted: 6 October 2024

First Online: 12 November 2024

Declarations

:

: The study was conducted according to the International Conference on Harmonisation guidelines and the Declaration of Helsinki. The trial protocol was approved by independent ethics committees and institutional review boards. Written informed consent was provided by patients ahead of study screening.

: Not applicable.

: XeB has received grant/research support from AbbVie and Novartis; consulting fees from AbbVie, BMS, Chugai, MSD, Novartis, Pfizer, and UCB Pharma; speakers’ bureau fees from AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, and UCB Pharma; is an editorial board member of the Annals of Rheumatic Diseases; is the ASAS President; and is the EULAR President-elect. DvdH has received consulting fees from AbbVie, ArgenX, BMS, Galapagos, GSK, Janssen, Lilly, Novartis, Pfizer, Takeda, and UCB Pharma; is an editorial board member of the Journal of Rheumatology, an editorial board member of RMD Open, an associate editor for the Annals of Rheumatic Diseases, an advisor for the Assessment of Axial Spondyloarthritis international Society, and the director of Imaging Rheumatology BV. JS has received grant/research support from AbbVie, Merck, and UCB; has been a consultant for AbbVie, Merck, Novartis, and UCB; and has served on the speakers’ bureau for AbbVie, Merck, and Novartis. RDI has received grant/research support from AbbVie, Amgen, Janssen, and Novartis; and has been a consultant for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and Sandoz. HK has received grant/research support from AbbVie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Eisai, and Mitsubishi-Tanabe; consulting fees from AbbVie, Janssen, Lilly, Novartis, Sanofi, and UCB; and received speakers’ bureau fees from AbbVie, Asahi-Kasei, BMS, Chugai, Eisai, Janssen, Lilly, Mitsubishi-Tanabe, Novartis, and Pfizer. WPM has received grant/research support from AbbVie, Novartis, Pfizer, and UCB Pharma; consulting fees, speaking fees, and/or honoraria fees from AbbVie, BMS, Celgene, Galapagos, Gilead, Janssen, Lilly, Medscape, Novartis, Peervoice, Pfizer, and UCB Pharma; is Chief Medical Officer of CARE Arthritis Limited; and has received royalties or licenses from Augurex for the 14-3-3eta diagnostic biomarker. IL-G, XiB, PW, KK, and AS are employees of AbbVie and may own stock or options. AD has received grant/research support from AbbVie, BMS, Celgene, Lilly, MoonLake, Novartis, Pfizer, and UCB Pharma; and honoraria or consultation fees from AbbVie, BMS, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma.